| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 233 | 2024 | 965 | 34.440 |
Why?
|
| Brain Ischemia | 80 | 2021 | 398 | 13.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 42 | 2023 | 378 | 7.880 |
Why?
|
| Cerebrovascular Disorders | 48 | 2023 | 143 | 5.940 |
Why?
|
| Ischemic Attack, Transient | 43 | 2022 | 181 | 5.610 |
Why?
|
| Carotid Stenosis | 24 | 2021 | 112 | 5.360 |
Why?
|
| Endarterectomy, Carotid | 26 | 2021 | 73 | 4.850 |
Why?
|
| Cerebral Hemorrhage | 20 | 2023 | 325 | 3.910 |
Why?
|
| Fibrinolytic Agents | 20 | 2016 | 202 | 3.530 |
Why?
|
| Humans | 382 | 2024 | 86653 | 3.110 |
Why?
|
| Delivery of Health Care | 15 | 2020 | 426 | 2.910 |
Why?
|
| Primary Prevention | 11 | 2021 | 85 | 2.510 |
Why?
|
| Risk Factors | 77 | 2022 | 5417 | 2.380 |
Why?
|
| Stroke Rehabilitation | 12 | 2022 | 41 | 2.380 |
Why?
|
| Hospitals | 11 | 2023 | 294 | 2.360 |
Why?
|
| Thrombolytic Therapy | 16 | 2019 | 220 | 2.300 |
Why?
|
| Intracranial Hemorrhages | 9 | 2023 | 120 | 2.190 |
Why?
|
| Aged | 132 | 2023 | 18415 | 2.120 |
Why?
|
| Atrial Fibrillation | 12 | 2023 | 288 | 2.120 |
Why?
|
| Medicare | 16 | 2023 | 410 | 2.100 |
Why?
|
| Cardiovascular Diseases | 23 | 2022 | 827 | 2.090 |
Why?
|
| Platelet Aggregation Inhibitors | 16 | 2021 | 134 | 1.980 |
Why?
|
| Hospital Mortality | 11 | 2019 | 349 | 1.930 |
Why?
|
| United States | 75 | 2023 | 6674 | 1.890 |
Why?
|
| Anticholesteremic Agents | 9 | 2023 | 137 | 1.880 |
Why?
|
| American Heart Association | 17 | 2023 | 92 | 1.880 |
Why?
|
| Neurology | 10 | 2020 | 70 | 1.870 |
Why?
|
| Brain | 29 | 2023 | 2216 | 1.820 |
Why?
|
| Patient Readmission | 8 | 2023 | 329 | 1.810 |
Why?
|
| Male | 190 | 2024 | 40973 | 1.800 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2019 | 162 | 1.780 |
Why?
|
| Female | 171 | 2024 | 44537 | 1.730 |
Why?
|
| Cholesterol, LDL | 14 | 2023 | 223 | 1.700 |
Why?
|
| Anticoagulants | 15 | 2023 | 408 | 1.690 |
Why?
|
| Islet Amyloid Polypeptide | 7 | 2023 | 25 | 1.690 |
Why?
|
| Hypertension | 17 | 2022 | 1142 | 1.690 |
Why?
|
| Aged, 80 and over | 56 | 2023 | 6509 | 1.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2018 | 508 | 1.540 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2021 | 7 | 1.530 |
Why?
|
| Recovery of Function | 8 | 2018 | 272 | 1.490 |
Why?
|
| Heptanoic Acids | 13 | 2014 | 72 | 1.440 |
Why?
|
| Health Services Accessibility | 13 | 2020 | 394 | 1.430 |
Why?
|
| Practice Guidelines as Topic | 15 | 2019 | 1036 | 1.420 |
Why?
|
| Secondary Prevention | 19 | 2022 | 162 | 1.380 |
Why?
|
| Hospitalization | 13 | 2023 | 849 | 1.360 |
Why?
|
| Pyrroles | 13 | 2014 | 184 | 1.330 |
Why?
|
| Cohort Studies | 26 | 2023 | 2767 | 1.330 |
Why?
|
| Middle Aged | 110 | 2020 | 25028 | 1.330 |
Why?
|
| Emergency Medical Services | 10 | 2014 | 209 | 1.310 |
Why?
|
| Severity of Illness Index | 16 | 2018 | 1801 | 1.270 |
Why?
|
| Dextroamphetamine | 6 | 2018 | 107 | 1.230 |
Why?
|
| Randomized Controlled Trials as Topic | 24 | 2019 | 865 | 1.220 |
Why?
|
| Glomerular Filtration Rate | 3 | 2018 | 385 | 1.220 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2017 | 11 | 1.200 |
Why?
|
| Biomedical Research | 8 | 2020 | 376 | 1.170 |
Why?
|
| Neuroprotective Agents | 7 | 2011 | 94 | 1.170 |
Why?
|
| Cognitive Dysfunction | 4 | 2023 | 132 | 1.160 |
Why?
|
| Alzheimer Disease | 9 | 2023 | 470 | 1.130 |
Why?
|
| Risk Assessment | 32 | 2019 | 2262 | 1.120 |
Why?
|
| Carotid Artery Diseases | 8 | 2011 | 97 | 1.110 |
Why?
|
| Central Nervous System Stimulants | 9 | 2018 | 216 | 1.100 |
Why?
|
| Cerebral Infarction | 9 | 2023 | 71 | 1.090 |
Why?
|
| Somatosensory Cortex | 9 | 2003 | 129 | 1.070 |
Why?
|
| Treatment Outcome | 48 | 2020 | 7993 | 1.060 |
Why?
|
| Neurologic Examination | 6 | 2017 | 118 | 1.060 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 4 | 2018 | 13 | 1.050 |
Why?
|
| Hypercholesterolemia | 8 | 2018 | 161 | 1.040 |
Why?
|
| Academic Medical Centers | 7 | 2020 | 379 | 1.030 |
Why?
|
| Emergency Service, Hospital | 10 | 2022 | 484 | 1.010 |
Why?
|
| Asymptomatic Diseases | 2 | 2014 | 41 | 0.990 |
Why?
|
| Dementia | 2 | 2023 | 187 | 0.990 |
Why?
|
| Aspirin | 8 | 2022 | 156 | 0.960 |
Why?
|
| Clinical Trials as Topic | 25 | 2011 | 1169 | 0.950 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2017 | 16 | 0.950 |
Why?
|
| Cholesterol | 7 | 2011 | 356 | 0.940 |
Why?
|
| Time-to-Treatment | 3 | 2015 | 98 | 0.910 |
Why?
|
| Mass Screening | 5 | 2021 | 618 | 0.910 |
Why?
|
| Motor Cortex | 7 | 2018 | 195 | 0.910 |
Why?
|
| Seasons | 2 | 2016 | 223 | 0.910 |
Why?
|
| Logistic Models | 15 | 2023 | 1187 | 0.900 |
Why?
|
| Odds Ratio | 16 | 2017 | 678 | 0.860 |
Why?
|
| Angioplasty | 5 | 2014 | 70 | 0.850 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2017 | 199 | 0.840 |
Why?
|
| Myocardial Infarction | 8 | 2023 | 376 | 0.840 |
Why?
|
| Health Policy | 7 | 2018 | 180 | 0.830 |
Why?
|
| Feeding Behavior | 3 | 2017 | 324 | 0.830 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 351 | 0.830 |
Why?
|
| Virus Diseases | 1 | 2022 | 97 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 12 | 2009 | 582 | 0.820 |
Why?
|
| Preventive Health Services | 4 | 2012 | 37 | 0.820 |
Why?
|
| Quality Indicators, Health Care | 3 | 2018 | 144 | 0.810 |
Why?
|
| Time Factors | 33 | 2018 | 5210 | 0.810 |
Why?
|
| Blood Pressure | 14 | 2016 | 1144 | 0.800 |
Why?
|
| Uganda | 5 | 2023 | 34 | 0.790 |
Why?
|
| Retrospective Studies | 31 | 2024 | 8491 | 0.780 |
Why?
|
| Stents | 7 | 2014 | 377 | 0.780 |
Why?
|
| Vision Disorders | 3 | 2017 | 75 | 0.780 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2020 | 56 | 0.770 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2015 | 122 | 0.760 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 36 | 0.760 |
Why?
|
| Adult | 71 | 2022 | 25649 | 0.760 |
Why?
|
| Health Education | 9 | 2018 | 101 | 0.760 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 160 | 0.750 |
Why?
|
| Financial Management | 1 | 2020 | 21 | 0.740 |
Why?
|
| Diet | 4 | 2021 | 443 | 0.730 |
Why?
|
| Coronary Disease | 11 | 2014 | 261 | 0.730 |
Why?
|
| Medicaid | 4 | 2023 | 217 | 0.720 |
Why?
|
| Models, Economic | 1 | 2020 | 60 | 0.720 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 56 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2021 | 1375 | 0.720 |
Why?
|
| Brain Injuries | 6 | 2006 | 161 | 0.720 |
Why?
|
| Databases, Factual | 8 | 2016 | 814 | 0.710 |
Why?
|
| Patient Discharge | 4 | 2023 | 300 | 0.710 |
Why?
|
| Memory Disorders | 1 | 2020 | 69 | 0.710 |
Why?
|
| Cytoprotection | 2 | 2009 | 47 | 0.700 |
Why?
|
| Physicians | 8 | 2013 | 673 | 0.690 |
Why?
|
| Influenza, Human | 1 | 2022 | 329 | 0.690 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 29 | 0.690 |
Why?
|
| Motor Activity | 7 | 2006 | 327 | 0.680 |
Why?
|
| Case-Control Studies | 11 | 2022 | 1806 | 0.680 |
Why?
|
| Mortality | 4 | 2018 | 149 | 0.680 |
Why?
|
| Disability Evaluation | 4 | 2017 | 136 | 0.680 |
Why?
|
| North Carolina | 13 | 2018 | 50 | 0.670 |
Why?
|
| Heart Diseases | 3 | 2011 | 290 | 0.670 |
Why?
|
| Acute Disease | 15 | 2014 | 826 | 0.670 |
Why?
|
| Blood Coagulation Tests | 4 | 2002 | 35 | 0.650 |
Why?
|
| Certification | 4 | 2015 | 58 | 0.650 |
Why?
|
| Antihypertensive Agents | 9 | 2022 | 521 | 0.650 |
Why?
|
| Quality of Health Care | 6 | 2020 | 380 | 0.640 |
Why?
|
| Predictive Value of Tests | 11 | 2019 | 1673 | 0.640 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 84 | 0.640 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 127 | 0.630 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 351 | 0.620 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2017 | 14 | 0.620 |
Why?
|
| Memory | 1 | 2020 | 225 | 0.620 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 102 | 0.610 |
Why?
|
| Health Care Surveys | 4 | 2010 | 278 | 0.610 |
Why?
|
| Age Factors | 15 | 2012 | 1851 | 0.610 |
Why?
|
| Reproducibility of Results | 15 | 2023 | 2705 | 0.600 |
Why?
|
| Evidence-Based Medicine | 10 | 2014 | 429 | 0.590 |
Why?
|
| Hospitals, Teaching | 2 | 2018 | 115 | 0.590 |
Why?
|
| Hypolipidemic Agents | 2 | 2014 | 102 | 0.580 |
Why?
|
| Rats | 30 | 2023 | 3992 | 0.580 |
Why?
|
| Neuronal Plasticity | 4 | 2008 | 187 | 0.570 |
Why?
|
| Prevalence | 9 | 2023 | 1239 | 0.570 |
Why?
|
| Prospective Studies | 14 | 2024 | 4213 | 0.570 |
Why?
|
| Dyslipidemias | 2 | 2014 | 109 | 0.570 |
Why?
|
| Blood Coagulation Disorders | 3 | 2002 | 63 | 0.560 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 311 | 0.550 |
Why?
|
| Choice Behavior | 1 | 2017 | 160 | 0.550 |
Why?
|
| Carotid Arteries | 6 | 2014 | 127 | 0.550 |
Why?
|
| Amphetamines | 7 | 2003 | 18 | 0.550 |
Why?
|
| White Matter | 3 | 2023 | 80 | 0.540 |
Why?
|
| Locomotion | 4 | 2006 | 131 | 0.540 |
Why?
|
| Cerebral Revascularization | 2 | 2012 | 26 | 0.540 |
Why?
|
| Registries | 11 | 2022 | 703 | 0.540 |
Why?
|
| Neuroimaging | 2 | 2017 | 113 | 0.540 |
Why?
|
| Norepinephrine | 7 | 2006 | 167 | 0.530 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 131 | 0.530 |
Why?
|
| Nervous System Diseases | 3 | 2015 | 151 | 0.520 |
Why?
|
| Animals | 54 | 2023 | 26589 | 0.520 |
Why?
|
| Neurotransmitter Agents | 5 | 2006 | 106 | 0.520 |
Why?
|
| Comorbidity | 9 | 2018 | 943 | 0.510 |
Why?
|
| National Health Programs | 2 | 2011 | 20 | 0.510 |
Why?
|
| Temperature | 1 | 2016 | 396 | 0.500 |
Why?
|
| Homocysteine | 3 | 2011 | 29 | 0.500 |
Why?
|
| Patient Care | 1 | 2015 | 100 | 0.500 |
Why?
|
| Disease Management | 5 | 2011 | 327 | 0.500 |
Why?
|
| Magnetic Resonance Angiography | 6 | 2011 | 262 | 0.490 |
Why?
|
| Models, Statistical | 4 | 2010 | 575 | 0.490 |
Why?
|
| Proportional Hazards Models | 9 | 2022 | 859 | 0.490 |
Why?
|
| Risk | 13 | 2019 | 674 | 0.490 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2004 | 45 | 0.490 |
Why?
|
| Precision Medicine | 1 | 2018 | 395 | 0.490 |
Why?
|
| Clinical Competence | 3 | 2013 | 751 | 0.470 |
Why?
|
| Biomarkers | 9 | 2023 | 1718 | 0.470 |
Why?
|
| Cough | 4 | 2008 | 54 | 0.470 |
Why?
|
| Hospitals, Veterans | 2 | 2003 | 17 | 0.470 |
Why?
|
| Central Nervous System Agents | 5 | 2003 | 15 | 0.460 |
Why?
|
| Prognosis | 14 | 2019 | 3680 | 0.460 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2012 | 2 | 0.450 |
Why?
|
| Deglutition Disorders | 4 | 2019 | 115 | 0.450 |
Why?
|
| Nootropic Agents | 1 | 2012 | 10 | 0.440 |
Why?
|
| Embolism | 2 | 2011 | 31 | 0.440 |
Why?
|
| Kidney Diseases | 1 | 2016 | 418 | 0.440 |
Why?
|
| Rural Health Services | 1 | 2012 | 13 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2015 | 2601 | 0.430 |
Why?
|
| Observer Variation | 9 | 2015 | 602 | 0.420 |
Why?
|
| Chi-Square Distribution | 8 | 2016 | 364 | 0.420 |
Why?
|
| Ambulatory Care | 1 | 2013 | 181 | 0.420 |
Why?
|
| Societies, Medical | 6 | 2018 | 572 | 0.410 |
Why?
|
| Hospital Rapid Response Team | 1 | 2011 | 27 | 0.410 |
Why?
|
| Movement Disorders | 4 | 2003 | 44 | 0.410 |
Why?
|
| Amphetamine | 7 | 2008 | 101 | 0.400 |
Why?
|
| Postural Balance | 8 | 2017 | 42 | 0.400 |
Why?
|
| Health Personnel | 4 | 2010 | 202 | 0.400 |
Why?
|
| Ultrasonography, Doppler, Duplex | 5 | 2011 | 40 | 0.400 |
Why?
|
| Patient Selection | 7 | 2011 | 686 | 0.400 |
Why?
|
| Amyloid beta-Peptides | 3 | 2023 | 203 | 0.390 |
Why?
|
| Behavior, Animal | 12 | 2008 | 373 | 0.390 |
Why?
|
| Organizations, Nonprofit | 1 | 2011 | 8 | 0.390 |
Why?
|
| Young Adult | 9 | 2019 | 5977 | 0.390 |
Why?
|
| Fee-for-Service Plans | 5 | 2022 | 30 | 0.390 |
Why?
|
| Cardiomegaly | 1 | 2011 | 111 | 0.380 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 218 | 0.380 |
Why?
|
| Patient Advocacy | 1 | 2011 | 49 | 0.380 |
Why?
|
| Patient Care Planning | 1 | 2011 | 81 | 0.380 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2009 | 62 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 86 | 0.380 |
Why?
|
| Recurrence | 14 | 2017 | 1139 | 0.380 |
Why?
|
| Ticlopidine | 2 | 2009 | 25 | 0.380 |
Why?
|
| Survivors | 4 | 2023 | 226 | 0.370 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 502 | 0.370 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1621 | 0.370 |
Why?
|
| Cardiology | 2 | 2011 | 123 | 0.370 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2262 | 0.370 |
Why?
|
| Corpus Striatum | 2 | 2009 | 86 | 0.360 |
Why?
|
| Surveys and Questionnaires | 10 | 2017 | 2501 | 0.360 |
Why?
|
| Athetosis | 1 | 2009 | 5 | 0.360 |
Why?
|
| Anomia | 1 | 2009 | 6 | 0.360 |
Why?
|
| Hospital Units | 1 | 2010 | 30 | 0.360 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 350 | 0.360 |
Why?
|
| Chorea | 1 | 2009 | 13 | 0.360 |
Why?
|
| Family Practice | 3 | 2003 | 84 | 0.360 |
Why?
|
| Health Services for the Aged | 1 | 2009 | 27 | 0.360 |
Why?
|
| Sensation Disorders | 1 | 2009 | 23 | 0.360 |
Why?
|
| Restaurants | 1 | 2009 | 5 | 0.360 |
Why?
|
| Adolescent | 16 | 2022 | 8982 | 0.360 |
Why?
|
| Diagnostic Imaging | 4 | 2011 | 469 | 0.360 |
Why?
|
| Ataxia | 1 | 2009 | 37 | 0.350 |
Why?
|
| Life Style | 3 | 2021 | 189 | 0.350 |
Why?
|
| Cerebral Angiography | 6 | 2002 | 196 | 0.350 |
Why?
|
| Heart Atria | 1 | 2011 | 250 | 0.350 |
Why?
|
| Sex Characteristics | 3 | 2008 | 319 | 0.350 |
Why?
|
| Coronary Angiography | 1 | 2010 | 232 | 0.350 |
Why?
|
| Intensive Care Units | 2 | 2020 | 374 | 0.350 |
Why?
|
| Critical Care | 1 | 2012 | 370 | 0.340 |
Why?
|
| Medication Adherence | 3 | 2020 | 129 | 0.340 |
Why?
|
| Triglycerides | 6 | 2014 | 232 | 0.340 |
Why?
|
| Medically Uninsured | 1 | 2009 | 58 | 0.340 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 2232 | 0.340 |
Why?
|
| Allied Health Personnel | 1 | 2008 | 19 | 0.340 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2008 | 3 | 0.330 |
Why?
|
| Government Programs | 1 | 2008 | 8 | 0.330 |
Why?
|
| Consumer Advocacy | 1 | 2008 | 10 | 0.330 |
Why?
|
| Double-Blind Method | 8 | 2018 | 1823 | 0.320 |
Why?
|
| Microvessels | 2 | 2019 | 70 | 0.320 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 999 | 0.320 |
Why?
|
| Drug Combinations | 5 | 2020 | 224 | 0.310 |
Why?
|
| Psychomotor Performance | 7 | 2008 | 492 | 0.310 |
Why?
|
| Coronary Artery Bypass | 1 | 2009 | 228 | 0.310 |
Why?
|
| Insecticides | 5 | 2008 | 27 | 0.310 |
Why?
|
| Carotid Artery, Internal | 2 | 2006 | 69 | 0.300 |
Why?
|
| Device Approval | 1 | 2007 | 13 | 0.300 |
Why?
|
| Algorithms | 7 | 2019 | 1830 | 0.300 |
Why?
|
| Data Collection | 7 | 2009 | 372 | 0.290 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 3640 | 0.290 |
Why?
|
| Taurine | 2 | 2004 | 11 | 0.290 |
Why?
|
| Physical Fitness | 3 | 2021 | 51 | 0.290 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 639 | 0.290 |
Why?
|
| Platelet Activation | 1 | 2006 | 13 | 0.280 |
Why?
|
| Research Design | 8 | 2022 | 594 | 0.280 |
Why?
|
| Vasculitis | 3 | 2005 | 39 | 0.280 |
Why?
|
| Dopamine Antagonists | 2 | 2003 | 35 | 0.280 |
Why?
|
| Guanidines | 3 | 2002 | 31 | 0.280 |
Why?
|
| Tamoxifen | 2 | 2004 | 168 | 0.270 |
Why?
|
| Incidence | 7 | 2020 | 1577 | 0.270 |
Why?
|
| Vertebral Artery Dissection | 1 | 2005 | 11 | 0.270 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2005 | 18 | 0.270 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2006 | 153 | 0.270 |
Why?
|
| Larynx | 1 | 2006 | 38 | 0.270 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 320 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2008 | 1221 | 0.260 |
Why?
|
| Hospitals, Special | 1 | 2005 | 7 | 0.260 |
Why?
|
| Foreign Bodies | 1 | 2006 | 63 | 0.260 |
Why?
|
| Catheter Ablation | 2 | 2022 | 233 | 0.260 |
Why?
|
| Alcohol Drinking | 3 | 2006 | 267 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 3362 | 0.250 |
Why?
|
| Sex Factors | 7 | 2010 | 1054 | 0.250 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 34 | 0.250 |
Why?
|
| Recombinant Proteins | 6 | 2018 | 1014 | 0.250 |
Why?
|
| Meta-Analysis as Topic | 4 | 2022 | 87 | 0.250 |
Why?
|
| Patient Education as Topic | 4 | 2017 | 351 | 0.250 |
Why?
|
| Erythrocytes | 2 | 2019 | 255 | 0.250 |
Why?
|
| Dermatan Sulfate | 3 | 2001 | 9 | 0.250 |
Why?
|
| Heparitin Sulfate | 3 | 2001 | 27 | 0.250 |
Why?
|
| Chlorine | 1 | 2004 | 8 | 0.250 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2004 | 14 | 0.250 |
Why?
|
| Magnesium Sulfate | 1 | 2004 | 15 | 0.240 |
Why?
|
| Salicylates | 1 | 2004 | 25 | 0.240 |
Why?
|
| Chondroitin Sulfates | 3 | 2001 | 43 | 0.240 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 60 | 0.240 |
Why?
|
| Axonal Transport | 1 | 2003 | 31 | 0.240 |
Why?
|
| Depression | 3 | 2024 | 473 | 0.240 |
Why?
|
| Breast Neoplasms | 4 | 2004 | 2903 | 0.240 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2003 | 1 | 0.240 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 487 | 0.240 |
Why?
|
| Program Evaluation | 2 | 2014 | 297 | 0.240 |
Why?
|
| Cell Membrane Permeability | 1 | 2004 | 119 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 150 | 0.230 |
Why?
|
| Social Marketing | 1 | 2003 | 10 | 0.230 |
Why?
|
| Ezetimibe | 1 | 2023 | 35 | 0.230 |
Why?
|
| Haloperidol | 3 | 2002 | 30 | 0.230 |
Why?
|
| Nerve Degeneration | 1 | 2003 | 83 | 0.230 |
Why?
|
| Thrombophilia | 1 | 2003 | 22 | 0.230 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 1991 | 0.230 |
Why?
|
| Dementia, Vascular | 1 | 2023 | 7 | 0.230 |
Why?
|
| Methylphenidate | 1 | 2003 | 10 | 0.230 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2003 | 143 | 0.230 |
Why?
|
| Capillaries | 1 | 2023 | 91 | 0.230 |
Why?
|
| Oocytes | 1 | 2004 | 221 | 0.230 |
Why?
|
| Clozapine | 1 | 2002 | 9 | 0.220 |
Why?
|
| DEET | 4 | 2004 | 6 | 0.220 |
Why?
|
| Critical Pathways | 2 | 2014 | 35 | 0.220 |
Why?
|
| Axons | 1 | 2003 | 174 | 0.220 |
Why?
|
| Serotonin Antagonists | 1 | 2002 | 35 | 0.220 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 231 | 0.220 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 806 | 0.220 |
Why?
|
| Markov Chains | 2 | 2012 | 125 | 0.220 |
Why?
|
| Speech | 2 | 2017 | 84 | 0.220 |
Why?
|
| Nicotine | 7 | 2006 | 194 | 0.220 |
Why?
|
| Hospital Bed Capacity | 2 | 2020 | 20 | 0.210 |
Why?
|
| Antidepressive Agents | 5 | 2012 | 106 | 0.210 |
Why?
|
| Sample Size | 1 | 2022 | 130 | 0.210 |
Why?
|
| Canada | 3 | 2013 | 204 | 0.210 |
Why?
|
| Telerehabilitation | 1 | 2022 | 1 | 0.210 |
Why?
|
| Williams Syndrome | 1 | 2022 | 4 | 0.210 |
Why?
|
| Aortic Stenosis, Supravalvular | 1 | 2022 | 4 | 0.210 |
Why?
|
| Ion Channels | 1 | 2004 | 246 | 0.210 |
Why?
|
| Transportation of Patients | 2 | 2014 | 32 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2357 | 0.210 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2001 | 5 | 0.210 |
Why?
|
| Age of Onset | 2 | 1999 | 310 | 0.210 |
Why?
|
| Embolism, Air | 1 | 2022 | 23 | 0.210 |
Why?
|
| Angiography | 1 | 2002 | 208 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2009 | 397 | 0.210 |
Why?
|
| Triage | 2 | 2020 | 108 | 0.210 |
Why?
|
| Air Pollution | 1 | 2023 | 68 | 0.210 |
Why?
|
| Air Pollutants | 1 | 2023 | 78 | 0.200 |
Why?
|
| Seizures | 1 | 2004 | 297 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2022 | 49 | 0.200 |
Why?
|
| Analysis of Variance | 6 | 2014 | 912 | 0.200 |
Why?
|
| Health Services Research | 4 | 2010 | 136 | 0.200 |
Why?
|
| Cholesterol, HDL | 4 | 2014 | 165 | 0.200 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 29 | 0.200 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 69 | 0.200 |
Why?
|
| Postoperative Complications | 6 | 2018 | 2207 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1999 | 157 | 0.190 |
Why?
|
| Infusions, Intravenous | 4 | 2014 | 429 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2018 | 839 | 0.190 |
Why?
|
| Metabolic Syndrome | 2 | 2013 | 142 | 0.190 |
Why?
|
| Sodium | 2 | 2017 | 341 | 0.190 |
Why?
|
| Health Resources | 3 | 2020 | 76 | 0.190 |
Why?
|
| Biometry | 2 | 2000 | 66 | 0.190 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 80 | 0.190 |
Why?
|
| Vaccination | 1 | 2022 | 254 | 0.190 |
Why?
|
| Anticonvulsants | 4 | 2004 | 126 | 0.190 |
Why?
|
| Drug Therapy, Combination | 8 | 2014 | 894 | 0.190 |
Why?
|
| Central Nervous System | 3 | 1999 | 151 | 0.180 |
Why?
|
| Epilepsy | 1 | 2004 | 397 | 0.180 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2006 | 45 | 0.180 |
Why?
|
| Cannabis | 2 | 2019 | 34 | 0.180 |
Why?
|
| Quality of Life | 6 | 2022 | 1585 | 0.180 |
Why?
|
| Intracranial Thrombosis | 2 | 2010 | 27 | 0.180 |
Why?
|
| Hospitals, Community | 2 | 2014 | 32 | 0.180 |
Why?
|
| Water Pipe Smoking | 1 | 2019 | 1 | 0.180 |
Why?
|
| Vascular Diseases | 2 | 2014 | 121 | 0.180 |
Why?
|
| Socioeconomic Factors | 4 | 2018 | 567 | 0.180 |
Why?
|
| Expert Testimony | 4 | 2004 | 46 | 0.180 |
Why?
|
| Social Class | 2 | 2014 | 128 | 0.170 |
Why?
|
| Diabetes Complications | 4 | 2008 | 207 | 0.170 |
Why?
|
| Arm | 2 | 2017 | 91 | 0.170 |
Why?
|
| Rural Population | 3 | 2022 | 136 | 0.170 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 63 | 0.170 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 129 | 0.170 |
Why?
|
| Brain Injury, Chronic | 1 | 1999 | 9 | 0.170 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 5 | 0.170 |
Why?
|
| Hospitals, Private | 1 | 2018 | 4 | 0.170 |
Why?
|
| Plasminogen Activators | 1 | 1998 | 11 | 0.170 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 18 | 0.170 |
Why?
|
| Diagnosis-Related Groups | 1 | 1998 | 20 | 0.170 |
Why?
|
| Drug Utilization | 3 | 2010 | 65 | 0.170 |
Why?
|
| Accelerometry | 1 | 2019 | 36 | 0.170 |
Why?
|
| Pyridostigmine Bromide | 3 | 2004 | 11 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 35 | 0.160 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2018 | 21 | 0.160 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1565 | 0.160 |
Why?
|
| Chloride Channels | 1 | 1998 | 42 | 0.160 |
Why?
|
| Guidelines as Topic | 3 | 2010 | 162 | 0.160 |
Why?
|
| Patient Compliance | 3 | 2017 | 227 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 113 | 0.160 |
Why?
|
| Neurologists | 1 | 2018 | 6 | 0.160 |
Why?
|
| Movement | 5 | 2002 | 299 | 0.160 |
Why?
|
| Antidotes | 1 | 2018 | 23 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2001 | 332 | 0.160 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 44 | 0.160 |
Why?
|
| Neopterin | 1 | 2017 | 2 | 0.160 |
Why?
|
| Chlorides | 1 | 1998 | 103 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2008 | 1961 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 3 | 2006 | 77 | 0.160 |
Why?
|
| Peroxidase | 1 | 2017 | 51 | 0.160 |
Why?
|
| Complex Mixtures | 1 | 2017 | 6 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2017 | 5 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2019 | 201 | 0.160 |
Why?
|
| Cultural Characteristics | 1 | 2017 | 19 | 0.160 |
Why?
|
| Osteopontin | 1 | 2017 | 47 | 0.150 |
Why?
|
| Food Labeling | 1 | 2017 | 8 | 0.150 |
Why?
|
| Atherosclerosis | 2 | 2013 | 245 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 15 | 0.150 |
Why?
|
| Temporomandibular Joint Dysfunction Syndrome | 1 | 1997 | 1 | 0.150 |
Why?
|
| Tongue Habits | 1 | 1997 | 1 | 0.150 |
Why?
|
| Primary Health Care | 2 | 1998 | 339 | 0.150 |
Why?
|
| Endarterectomy | 1 | 1997 | 20 | 0.150 |
Why?
|
| Neck Muscles | 1 | 1997 | 16 | 0.150 |
Why?
|
| Food | 2 | 2009 | 86 | 0.150 |
Why?
|
| Advisory Committees | 2 | 2010 | 90 | 0.150 |
Why?
|
| Linear Models | 3 | 2014 | 421 | 0.150 |
Why?
|
| Permethrin | 4 | 2004 | 9 | 0.150 |
Why?
|
| Focus Groups | 1 | 2017 | 155 | 0.150 |
Why?
|
| Comprehension | 1 | 2017 | 79 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2000 | 347 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 297 | 0.150 |
Why?
|
| Food Preferences | 1 | 2016 | 26 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 1999 | 252 | 0.140 |
Why?
|
| Length of Stay | 3 | 2009 | 703 | 0.140 |
Why?
|
| Functional Laterality | 3 | 2001 | 201 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2011 | 371 | 0.140 |
Why?
|
| Eye | 1 | 2017 | 111 | 0.140 |
Why?
|
| Psychotropic Drugs | 1 | 1997 | 75 | 0.140 |
Why?
|
| Tertiary Care Centers | 2 | 2016 | 94 | 0.140 |
Why?
|
| Hepatitis B | 2 | 2011 | 74 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2017 | 256 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2009 | 1538 | 0.140 |
Why?
|
| Psychotherapy, Group | 1 | 2016 | 33 | 0.140 |
Why?
|
| Ethics, Medical | 4 | 2020 | 306 | 0.140 |
Why?
|
| Troponin | 1 | 2016 | 24 | 0.140 |
Why?
|
| Face | 1 | 2017 | 114 | 0.140 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2011 | 344 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 454 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 45 | 0.140 |
Why?
|
| Policy Making | 1 | 2016 | 62 | 0.140 |
Why?
|
| Stroke, Lacunar | 1 | 2015 | 4 | 0.140 |
Why?
|
| Obesity | 5 | 2018 | 964 | 0.140 |
Why?
|
| Urban Population | 2 | 2022 | 213 | 0.140 |
Why?
|
| Lipoproteins, HDL | 2 | 2013 | 96 | 0.140 |
Why?
|
| Liver Transplantation | 5 | 2011 | 1268 | 0.140 |
Why?
|
| Causality | 2 | 2009 | 81 | 0.140 |
Why?
|
| Carcinoma | 1 | 1999 | 436 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2018 | 460 | 0.140 |
Why?
|
| Acetylcholinesterase | 6 | 2008 | 47 | 0.140 |
Why?
|
| Potassium | 2 | 2003 | 281 | 0.130 |
Why?
|
| Pancreas | 3 | 2023 | 239 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 1995 | 87 | 0.130 |
Why?
|
| Myocardium | 1 | 1998 | 529 | 0.130 |
Why?
|
| Reaction Time | 1 | 2017 | 309 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2018 | 355 | 0.130 |
Why?
|
| Eating | 1 | 2016 | 166 | 0.130 |
Why?
|
| Attitude | 1 | 2016 | 127 | 0.130 |
Why?
|
| Fibromuscular Dysplasia | 2 | 1995 | 11 | 0.130 |
Why?
|
| Clinical Protocols | 3 | 2014 | 156 | 0.130 |
Why?
|
| Mental Disorders | 1 | 1998 | 371 | 0.130 |
Why?
|
| Nerve Regeneration | 2 | 1997 | 32 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 257 | 0.130 |
Why?
|
| Sympathomimetics | 3 | 2006 | 12 | 0.130 |
Why?
|
| Craniocerebral Trauma | 1 | 1995 | 52 | 0.130 |
Why?
|
| Chlorpyrifos | 2 | 2006 | 4 | 0.130 |
Why?
|
| Blood Platelet Disorders | 1 | 2014 | 9 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 41 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2014 | 13 | 0.130 |
Why?
|
| Geographic Information Systems | 1 | 2014 | 20 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2014 | 19 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Education, Medical, Continuing | 3 | 2010 | 107 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1686 | 0.130 |
Why?
|
| Motor Skills | 2 | 2017 | 71 | 0.130 |
Why?
|
| Motivation | 1 | 2017 | 287 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2014 | 30 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 87 | 0.120 |
Why?
|
| Warfarin | 3 | 2001 | 103 | 0.120 |
Why?
|
| Survival Rate | 3 | 2012 | 1863 | 0.120 |
Why?
|
| Teaching | 1 | 2015 | 147 | 0.120 |
Why?
|
| Sequence Homology | 1 | 1994 | 28 | 0.120 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2013 | 6 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2016 | 170 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2007 | 231 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2008 | 150 | 0.120 |
Why?
|
| Electroencephalography | 15 | 1973 | 709 | 0.120 |
Why?
|
| Smoking | 4 | 2018 | 609 | 0.120 |
Why?
|
| Niacin | 1 | 2013 | 37 | 0.120 |
Why?
|
| Foramen Ovale, Patent | 1 | 2013 | 18 | 0.110 |
Why?
|
| Physical Examination | 1 | 1994 | 149 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2004 | 28 | 0.110 |
Why?
|
| Insect Repellents | 2 | 2004 | 3 | 0.110 |
Why?
|
| Sequence Alignment | 1 | 1994 | 351 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1999 | 1313 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2015 | 482 | 0.110 |
Why?
|
| Cerebral Cortex | 9 | 2002 | 584 | 0.110 |
Why?
|
| Hepatitis B virus | 2 | 2011 | 43 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2014 | 197 | 0.110 |
Why?
|
| Dizocilpine Maleate | 1 | 1992 | 12 | 0.110 |
Why?
|
| Clinical Coding | 1 | 2012 | 23 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2014 | 236 | 0.110 |
Why?
|
| Deglutition | 2 | 2019 | 73 | 0.110 |
Why?
|
| Inflammation | 4 | 2023 | 924 | 0.110 |
Why?
|
| Leukemia | 1 | 2014 | 320 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2014 | 223 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1993 | 155 | 0.110 |
Why?
|
| Thrombectomy | 2 | 2018 | 158 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2014 | 280 | 0.110 |
Why?
|
| Antioxidants | 2 | 2004 | 223 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 4 | 2009 | 159 | 0.100 |
Why?
|
| Aging | 2 | 2021 | 691 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2003 | 26 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 2271 | 0.100 |
Why?
|
| Medical Records | 3 | 2016 | 119 | 0.100 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 24 | 0.100 |
Why?
|
| Injections, Intravenous | 3 | 2009 | 244 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2014 | 428 | 0.100 |
Why?
|
| Voluntary Health Agencies | 1 | 2011 | 5 | 0.100 |
Why?
|
| Pyrethrins | 2 | 2001 | 10 | 0.100 |
Why?
|
| GABA Agents | 2 | 2003 | 8 | 0.100 |
Why?
|
| Muscle Spasticity | 1 | 2011 | 9 | 0.100 |
Why?
|
| Lobbying | 1 | 2011 | 3 | 0.100 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 35 | 0.100 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2003 | 34 | 0.100 |
Why?
|
| Cryosurgery | 1 | 2011 | 41 | 0.100 |
Why?
|
| Nucleosides | 1 | 2011 | 22 | 0.100 |
Why?
|
| Hyperhomocysteinemia | 2 | 2001 | 11 | 0.100 |
Why?
|
| Phenotype | 2 | 2010 | 2380 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 346 | 0.100 |
Why?
|
| Neuromuscular Diseases | 1 | 2011 | 30 | 0.100 |
Why?
|
| Smoking Cessation | 2 | 2019 | 230 | 0.100 |
Why?
|
| Attention | 3 | 1991 | 388 | 0.100 |
Why?
|
| Contraceptives, Oral | 2 | 2001 | 46 | 0.100 |
Why?
|
| Receptors, Nicotinic | 4 | 2008 | 129 | 0.100 |
Why?
|
| Lipoproteins | 1 | 2011 | 135 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2010 | 92 | 0.090 |
Why?
|
| Nucleotides | 1 | 2011 | 95 | 0.090 |
Why?
|
| Nutritional Status | 2 | 2001 | 83 | 0.090 |
Why?
|
| Rats, Inbred Strains | 4 | 1992 | 312 | 0.090 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 31 | 0.090 |
Why?
|
| Forecasting | 2 | 2010 | 304 | 0.090 |
Why?
|
| Electric Fish | 1 | 1990 | 18 | 0.090 |
Why?
|
| Health Priorities | 1 | 2010 | 23 | 0.090 |
Why?
|
| Thrombosis | 1 | 2013 | 296 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2011 | 119 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 190 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 2 | 2006 | 212 | 0.090 |
Why?
|
| Clonidine | 1 | 1990 | 37 | 0.090 |
Why?
|
| Drug Interactions | 5 | 2019 | 248 | 0.090 |
Why?
|
| Health Status | 4 | 2017 | 360 | 0.090 |
Why?
|
| Venous Thrombosis | 2 | 2010 | 243 | 0.090 |
Why?
|
| Vitamin K | 1 | 2009 | 25 | 0.090 |
Why?
|
| Bias | 2 | 2000 | 127 | 0.090 |
Why?
|
| Community Health Planning | 2 | 2014 | 21 | 0.090 |
Why?
|
| Latin America | 1 | 2009 | 14 | 0.090 |
Why?
|
| Amyloid | 2 | 2020 | 85 | 0.090 |
Why?
|
| Risk Reduction Behavior | 3 | 2006 | 98 | 0.090 |
Why?
|
| Domestic Violence | 1 | 2009 | 24 | 0.090 |
Why?
|
| Telephone | 1 | 2009 | 32 | 0.090 |
Why?
|
| Hemorrhage | 3 | 2009 | 268 | 0.090 |
Why?
|
| Computer Simulation | 1 | 1994 | 1078 | 0.090 |
Why?
|
| Professional Practice | 3 | 2004 | 46 | 0.090 |
Why?
|
| Kidney | 4 | 2019 | 1242 | 0.080 |
Why?
|
| Physical Conditioning, Animal | 1 | 2008 | 19 | 0.080 |
Why?
|
| Anemia, Sickle Cell | 2 | 2001 | 131 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 294 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 2 | 2002 | 220 | 0.080 |
Why?
|
| Pneumonia, Aspiration | 1 | 2008 | 19 | 0.080 |
Why?
|
| Global Health | 1 | 2010 | 193 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 677 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 148 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1981 | 0.080 |
Why?
|
| Nitro Compounds | 1 | 2008 | 2 | 0.080 |
Why?
|
| Lip | 1 | 1988 | 16 | 0.080 |
Why?
|
| Phonetics | 1 | 1988 | 36 | 0.080 |
Why?
|
| ROC Curve | 2 | 2017 | 752 | 0.080 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 58 | 0.080 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 71 | 0.080 |
Why?
|
| Disease Progression | 2 | 2010 | 1531 | 0.080 |
Why?
|
| Lipids | 2 | 2007 | 269 | 0.080 |
Why?
|
| Research | 1 | 2009 | 253 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2003 | 328 | 0.080 |
Why?
|
| Tongue | 1 | 1988 | 57 | 0.080 |
Why?
|
| Language | 1 | 2009 | 151 | 0.080 |
Why?
|
| Butyrylcholinesterase | 5 | 2008 | 10 | 0.080 |
Why?
|
| Likelihood Functions | 2 | 2006 | 251 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 878 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2011 | 34 | 0.080 |
Why?
|
| Health Care Rationing | 2 | 2020 | 83 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2008 | 90 | 0.080 |
Why?
|
| Reticular Formation | 4 | 1975 | 17 | 0.070 |
Why?
|
| United Kingdom | 2 | 2017 | 164 | 0.070 |
Why?
|
| Intraoperative Complications | 2 | 1999 | 185 | 0.070 |
Why?
|
| Receptors, Muscarinic | 5 | 2008 | 49 | 0.070 |
Why?
|
| Imidazoles | 1 | 2008 | 162 | 0.070 |
Why?
|
| Hyperlipidemias | 2 | 2008 | 95 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2011 | 229 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2001 | 394 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2010 | 596 | 0.070 |
Why?
|
| RNA | 1 | 2010 | 560 | 0.070 |
Why?
|
| P-Selectin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1464 | 0.070 |
Why?
|
| Telemedicine | 2 | 2020 | 169 | 0.070 |
Why?
|
| Educational Status | 2 | 2005 | 188 | 0.070 |
Why?
|
| Health Behavior | 3 | 2018 | 183 | 0.070 |
Why?
|
| Biopsy | 2 | 2008 | 1163 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 1019 | 0.070 |
Why?
|
| Benchmarking | 2 | 2023 | 78 | 0.070 |
Why?
|
| Moyamoya Disease | 1 | 2005 | 14 | 0.070 |
Why?
|
| Maternal Exposure | 1 | 2006 | 57 | 0.070 |
Why?
|
| Hippocampus | 5 | 1990 | 442 | 0.070 |
Why?
|
| Women's Health | 1 | 2006 | 100 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2004 | 16 | 0.070 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 46 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2005 | 54 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2005 | 24 | 0.070 |
Why?
|
| Purkinje Cells | 1 | 2006 | 80 | 0.070 |
Why?
|
| Hypotonic Solutions | 2 | 1998 | 8 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2010 | 926 | 0.070 |
Why?
|
| Placebos | 9 | 2009 | 218 | 0.070 |
Why?
|
| Sympatholytics | 3 | 1997 | 6 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2005 | 71 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2006 | 137 | 0.060 |
Why?
|
| Ethics, Professional | 1 | 2004 | 10 | 0.060 |
Why?
|
| Osmolar Concentration | 2 | 1998 | 181 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 740 | 0.060 |
Why?
|
| Illusions | 1 | 2004 | 12 | 0.060 |
Why?
|
| Retinal Artery Occlusion | 1 | 2004 | 12 | 0.060 |
Why?
|
| Administration, Oral | 4 | 2012 | 684 | 0.060 |
Why?
|
| Trout | 1 | 2004 | 2 | 0.060 |
Why?
|
| Malathion | 1 | 2004 | 1 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 2 | 2000 | 23 | 0.060 |
Why?
|
| Rubidium | 1 | 2004 | 9 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2004 | 66 | 0.060 |
Why?
|
| Biological Transport | 2 | 1998 | 396 | 0.060 |
Why?
|
| Alaska | 1 | 2023 | 17 | 0.060 |
Why?
|
| Speech Therapy | 1 | 2003 | 8 | 0.060 |
Why?
|
| Emergency Medical Technicians | 1 | 2003 | 14 | 0.060 |
Why?
|
| Endocarditis | 1 | 2003 | 18 | 0.060 |
Why?
|
| Military Personnel | 1 | 2005 | 85 | 0.060 |
Why?
|
| Xenopus laevis | 1 | 2004 | 137 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2001 | 78 | 0.060 |
Why?
|
| Occupational Therapy | 1 | 2003 | 16 | 0.060 |
Why?
|
| Wales | 1 | 2003 | 10 | 0.060 |
Why?
|
| Television | 1 | 2003 | 29 | 0.060 |
Why?
|
| Microcirculation | 2 | 2019 | 106 | 0.060 |
Why?
|
| England | 1 | 2003 | 41 | 0.060 |
Why?
|
| Rats, Transgenic | 1 | 2023 | 6 | 0.060 |
Why?
|
| Mass Media | 1 | 2003 | 26 | 0.060 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 58 | 0.060 |
Why?
|
| Therapeutics | 1 | 2003 | 12 | 0.060 |
Why?
|
| Tranquilizing Agents | 5 | 1973 | 7 | 0.060 |
Why?
|
| Nitrogen Dioxide | 1 | 2023 | 11 | 0.060 |
Why?
|
| Pregnancy | 3 | 2008 | 2894 | 0.060 |
Why?
|
| Europe | 1 | 2004 | 309 | 0.060 |
Why?
|
| Amyloidogenic Proteins | 1 | 2023 | 13 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2003 | 24 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 646 | 0.060 |
Why?
|
| Vegetables | 1 | 2003 | 45 | 0.060 |
Why?
|
| Denmark | 1 | 2022 | 15 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2023 | 58 | 0.060 |
Why?
|
| Heart Valve Diseases | 1 | 2003 | 109 | 0.060 |
Why?
|
| Fruit | 1 | 2003 | 75 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2003 | 65 | 0.050 |
Why?
|
| Receptor, Muscarinic M2 | 4 | 2003 | 11 | 0.050 |
Why?
|
| Sarin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 85 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2003 | 114 | 0.050 |
Why?
|
| Hematoma | 1 | 2023 | 104 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 263 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2023 | 79 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2004 | 241 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 121 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 678 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2003 | 128 | 0.050 |
Why?
|
| Body Weight | 2 | 2004 | 459 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 165 | 0.050 |
Why?
|
| Collagen | 1 | 2023 | 269 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2003 | 222 | 0.050 |
Why?
|
| Bacteroides Infections | 1 | 2001 | 8 | 0.050 |
Why?
|
| Heart Rate | 2 | 2023 | 492 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2003 | 248 | 0.050 |
Why?
|
| Metronidazole | 1 | 2001 | 26 | 0.050 |
Why?
|
| Ethics Committees, Research | 1 | 2021 | 33 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 636 | 0.050 |
Why?
|
| Research Personnel | 2 | 2004 | 67 | 0.050 |
Why?
|
| Radiography | 1 | 2003 | 813 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2001 | 33 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2002 | 132 | 0.050 |
Why?
|
| Methaqualone | 2 | 1971 | 2 | 0.050 |
Why?
|
| Glutethimide | 2 | 1971 | 3 | 0.050 |
Why?
|
| Catheterization | 1 | 2002 | 232 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 152 | 0.050 |
Why?
|
| Bacteroides fragilis | 1 | 2001 | 42 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 40 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2002 | 116 | 0.050 |
Why?
|
| Sex Distribution | 2 | 1998 | 173 | 0.050 |
Why?
|
| Inhalation | 1 | 2001 | 31 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 40 | 0.050 |
Why?
|
| Lamivudine | 1 | 2000 | 13 | 0.050 |
Why?
|
| Arteries | 1 | 2022 | 177 | 0.050 |
Why?
|
| Physician's Role | 2 | 2018 | 179 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 23 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2001 | 70 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2002 | 278 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2000 | 71 | 0.050 |
Why?
|
| Disclosure | 1 | 2021 | 108 | 0.050 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 1971 | 50 | 0.050 |
Why?
|
| Testis | 1 | 2001 | 152 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2023 | 296 | 0.050 |
Why?
|
| Total Quality Management | 1 | 2000 | 34 | 0.050 |
Why?
|
| Estradiol | 1 | 2001 | 252 | 0.050 |
Why?
|
| Finland | 1 | 1999 | 29 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 5 | 1973 | 125 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2000 | 148 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2000 | 996 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2005 | 141 | 0.050 |
Why?
|
| Eicosanoids | 1 | 2019 | 16 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 335 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 92 | 0.040 |
Why?
|
| Glycosaminoglycans | 2 | 1990 | 47 | 0.040 |
Why?
|
| Administration, Topical | 3 | 2006 | 95 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2000 | 83 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 1999 | 65 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 2019 | 52 | 0.040 |
Why?
|
| Infant | 2 | 2023 | 3047 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2001 | 182 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2019 | 91 | 0.040 |
Why?
|
| Liver | 3 | 2019 | 1230 | 0.040 |
Why?
|
| Cineradiography | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 1540 | 0.040 |
Why?
|
| Sampling Studies | 2 | 2000 | 70 | 0.040 |
Why?
|
| Cerebral Arteries | 1 | 1999 | 74 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 1999 | 53 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2019 | 66 | 0.040 |
Why?
|
| Axilla | 1 | 1999 | 99 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2019 | 28 | 0.040 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1998 | 14 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2018 | 21 | 0.040 |
Why?
|
| Insurance Benefits | 1 | 2018 | 8 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2000 | 123 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2019 | 63 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 1999 | 81 | 0.040 |
Why?
|
| Cell Size | 1 | 1998 | 65 | 0.040 |
Why?
|
| Factor Xa | 1 | 2018 | 4 | 0.040 |
Why?
|
| Child | 4 | 2006 | 6928 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 162 | 0.040 |
Why?
|
| Cytosol | 1 | 1998 | 189 | 0.040 |
Why?
|
| Mice | 3 | 2023 | 11356 | 0.040 |
Why?
|
| Oxidopamine | 1 | 1997 | 8 | 0.040 |
Why?
|
| Dopamine Agents | 1 | 1998 | 29 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2018 | 52 | 0.040 |
Why?
|
| Arginine | 1 | 2018 | 136 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2010 | 1204 | 0.040 |
Why?
|
| Rats, Mutant Strains | 1 | 2017 | 23 | 0.040 |
Why?
|
| Muscles | 2 | 1995 | 194 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 468 | 0.040 |
Why?
|
| Maze Learning | 1 | 2017 | 28 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1999 | 217 | 0.040 |
Why?
|
| Cause of Death | 2 | 2000 | 277 | 0.040 |
Why?
|
| Health Surveys | 1 | 1998 | 239 | 0.040 |
Why?
|
| Diplopia | 1 | 2017 | 13 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 1997 | 46 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2018 | 73 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 27 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 1998 | 273 | 0.040 |
Why?
|
| Cell Count | 1 | 1997 | 195 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 166 | 0.040 |
Why?
|
| Endothelium | 1 | 2017 | 59 | 0.040 |
Why?
|
| Echocardiography | 2 | 2009 | 911 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 77 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2003 | 2379 | 0.040 |
Why?
|
| Israel | 3 | 2005 | 55 | 0.040 |
Why?
|
| Coccidioidomycosis | 1 | 1997 | 7 | 0.040 |
Why?
|
| Knowledge | 1 | 1997 | 29 | 0.040 |
Why?
|
| Intestines | 1 | 2000 | 411 | 0.040 |
Why?
|
| Psychometrics | 1 | 1998 | 327 | 0.040 |
Why?
|
| Consciousness Disorders | 1 | 1997 | 9 | 0.040 |
Why?
|
| Attitude to Health | 1 | 1998 | 220 | 0.040 |
Why?
|
| Videotape Recording | 1 | 1997 | 47 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 1998 | 510 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Electromyography | 1 | 1997 | 183 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 303 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2010 | 548 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 989 | 0.040 |
Why?
|
| Awareness | 1 | 1997 | 93 | 0.040 |
Why?
|
| Piperazines | 1 | 2018 | 272 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2008 | 80 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2017 | 149 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1998 | 262 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 1997 | 284 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 746 | 0.030 |
Why?
|
| Neurosurgery | 1 | 1997 | 84 | 0.030 |
Why?
|
| Gene Products, tat | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 175 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 112 | 0.030 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1995 | 27 | 0.030 |
Why?
|
| Tobacco Products | 1 | 2016 | 41 | 0.030 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 35 | 0.030 |
Why?
|
| Pipecolic Acids | 1 | 1995 | 14 | 0.030 |
Why?
|
| Reflex | 3 | 2002 | 79 | 0.030 |
Why?
|
| Gene Expression | 1 | 2000 | 1284 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1995 | 40 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 1995 | 47 | 0.030 |
Why?
|
| Suction | 1 | 1995 | 35 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1995 | 103 | 0.030 |
Why?
|
| Actins | 1 | 1998 | 451 | 0.030 |
Why?
|
| Chlordiazepoxide | 4 | 1971 | 4 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2000 | 1924 | 0.030 |
Why?
|
| Cholinesterases | 2 | 2006 | 17 | 0.030 |
Why?
|
| Ethanol | 2 | 1969 | 249 | 0.030 |
Why?
|
| Speech Perception | 1 | 1995 | 71 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 30 | 0.030 |
Why?
|
| Hindlimb | 1 | 1995 | 89 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 155 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2015 | 971 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 190 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2000 | 265 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1999 | 568 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1999 | 1939 | 0.030 |
Why?
|
| Color Perception | 1 | 1995 | 117 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1994 | 80 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 916 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 173 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 1994 | 42 | 0.030 |
Why?
|
| Mathematics | 1 | 1994 | 190 | 0.030 |
Why?
|
| Leg | 1 | 1994 | 137 | 0.030 |
Why?
|
| China | 1 | 2014 | 228 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 172 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1996 | 695 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 715 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 78 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 116 | 0.030 |
Why?
|
| Biological Assay | 1 | 1993 | 78 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 3095 | 0.030 |
Why?
|
| Hand Strength | 2 | 2004 | 51 | 0.030 |
Why?
|
| Simvastatin | 1 | 2013 | 106 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 1973 | 73 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 1994 | 116 | 0.030 |
Why?
|
| Heart Valves | 1 | 2012 | 13 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 930 | 0.030 |
Why?
|
| Phosphoglycerate Kinase | 1 | 1992 | 17 | 0.030 |
Why?
|
| Meprobamate | 3 | 1971 | 3 | 0.030 |
Why?
|
| Phenobarbital | 3 | 1971 | 33 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2819 | 0.030 |
Why?
|
| Vibrissae | 2 | 2002 | 10 | 0.030 |
Why?
|
| Cholangitis, Sclerosing | 1 | 1992 | 52 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1972 | 281 | 0.030 |
Why?
|
| Hallucinogens | 1 | 1973 | 71 | 0.030 |
Why?
|
| Adrenergic Agents | 2 | 1961 | 6 | 0.030 |
Why?
|
| Meiosis | 1 | 1992 | 80 | 0.030 |
Why?
|
| Posture | 2 | 2002 | 125 | 0.030 |
Why?
|
| X Chromosome | 1 | 1992 | 152 | 0.030 |
Why?
|
| Brain Stem | 2 | 2002 | 165 | 0.030 |
Why?
|
| Statistics as Topic | 3 | 1989 | 238 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2011 | 36 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 83 | 0.020 |
Why?
|
| Urea | 1 | 1971 | 57 | 0.020 |
Why?
|
| Microcomputers | 1 | 1991 | 26 | 0.020 |
Why?
|
| Jaw, Edentulous | 1 | 1990 | 6 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 1991 | 86 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 96 | 0.020 |
Why?
|
| Glutamates | 1 | 1990 | 89 | 0.020 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1990 | 3 | 0.020 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1990 | 17 | 0.020 |
Why?
|
| Calcimycin | 1 | 1990 | 33 | 0.020 |
Why?
|
| Technology | 1 | 2010 | 29 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1972 | 580 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 27 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
| Nervous System | 1 | 1990 | 86 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 102 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1993 | 313 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1990 | 137 | 0.020 |
Why?
|
| Hormones | 1 | 2010 | 141 | 0.020 |
Why?
|
| Communication | 1 | 1994 | 441 | 0.020 |
Why?
|
| Mammography | 1 | 1993 | 463 | 0.020 |
Why?
|
| Heart | 2 | 1971 | 539 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 127 | 0.020 |
Why?
|
| Intergenerational Relations | 1 | 2009 | 5 | 0.020 |
Why?
|
| Lithium | 1 | 1969 | 59 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2010 | 175 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 369 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1969 | 144 | 0.020 |
Why?
|
| Sleep | 4 | 1971 | 444 | 0.020 |
Why?
|
| HIV-2 | 1 | 1988 | 4 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1999 | 2438 | 0.020 |
Why?
|
| Public Health | 1 | 2010 | 129 | 0.020 |
Why?
|
| Proviruses | 1 | 1988 | 15 | 0.020 |
Why?
|
| Public Policy | 1 | 2009 | 52 | 0.020 |
Why?
|
| Geography | 1 | 2010 | 223 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2010 | 312 | 0.020 |
Why?
|
| Rabbits | 5 | 1973 | 636 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 174 | 0.020 |
Why?
|
| Pulmonary Ventilation | 1 | 2008 | 32 | 0.020 |
Why?
|
| Alcoholism | 1 | 1990 | 172 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2018 | 1004 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2008 | 31 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2008 | 119 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2009 | 105 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 78 | 0.020 |
Why?
|
| Pharmacology | 2 | 1965 | 11 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2008 | 14 | 0.020 |
Why?
|
| Neonicotinoids | 1 | 2008 | 1 | 0.020 |
Why?
|
| Gestures | 1 | 1988 | 10 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2010 | 361 | 0.020 |
Why?
|
| Neural Pathways | 1 | 1990 | 308 | 0.020 |
Why?
|
| Internet | 1 | 2010 | 312 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2008 | 76 | 0.020 |
Why?
|
| Speech Acoustics | 1 | 1988 | 22 | 0.020 |
Why?
|
| HIV-1 | 1 | 1988 | 163 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2010 | 448 | 0.020 |
Why?
|
| Age Distribution | 2 | 1998 | 204 | 0.020 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 977 | 0.020 |
Why?
|
| Injections, Subcutaneous | 2 | 2006 | 117 | 0.020 |
Why?
|
| Anxiety | 2 | 1971 | 287 | 0.020 |
Why?
|
| Proteins | 1 | 1972 | 777 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1994 | 754 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 478 | 0.020 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2007 | 59 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 11 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 3613 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 25 | 0.020 |
Why?
|
| Cognition | 1 | 1991 | 570 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 152 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 1992 | 711 | 0.020 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2005 | 12 | 0.020 |
Why?
|
| Strikes, Employee | 1 | 1984 | 1 | 0.020 |
Why?
|
| Alcohols | 1 | 1964 | 14 | 0.020 |
Why?
|
| Codes of Ethics | 1 | 2004 | 12 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 256 | 0.020 |
Why?
|
| Marketing of Health Services | 1 | 2004 | 15 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2004 | 31 | 0.020 |
Why?
|
| Dysarthria | 1 | 2004 | 6 | 0.020 |
Why?
|
| Paranoid Disorders | 1 | 2004 | 5 | 0.020 |
Why?
|
| Quadriplegia | 1 | 2004 | 22 | 0.020 |
Why?
|
| Nystagmus, Pathologic | 1 | 2004 | 33 | 0.020 |
Why?
|
| Social Responsibility | 1 | 2004 | 57 | 0.020 |
Why?
|
| Human Experimentation | 1 | 2004 | 39 | 0.020 |
Why?
|
| Environment | 1 | 1966 | 219 | 0.020 |
Why?
|
| Fecal Incontinence | 1 | 2004 | 57 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2004 | 21 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2004 | 67 | 0.020 |
Why?
|
| Malpractice | 1 | 2004 | 57 | 0.020 |
Why?
|
| Vertigo | 1 | 2004 | 42 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2004 | 46 | 0.020 |
Why?
|
| Drug Industry | 1 | 2004 | 54 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2004 | 66 | 0.020 |
Why?
|
| Caregivers | 1 | 2005 | 151 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2004 | 87 | 0.010 |
Why?
|
| Prednisone | 1 | 2004 | 258 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 299 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 243 | 0.010 |
Why?
|
| Postmenopause | 1 | 2004 | 98 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2005 | 219 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 446 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1964 | 148 | 0.010 |
Why?
|
| Graft Survival | 2 | 2000 | 884 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1992 | 1921 | 0.010 |
Why?
|
| Sodium Chloride | 2 | 1973 | 88 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2003 | 176 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2003 | 60 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2002 | 70 | 0.010 |
Why?
|
| Government | 1 | 2002 | 9 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 113 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2004 | 206 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 145 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 27 | 0.010 |
Why?
|
| State Government | 1 | 2002 | 20 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 433 | 0.010 |
Why?
|
| Orientation | 1 | 2002 | 119 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 770 | 0.010 |
Why?
|
| Hexamethonium Compounds | 1 | 2001 | 6 | 0.010 |
Why?
|
| Accreditation | 1 | 2002 | 60 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2001 | 23 | 0.010 |
Why?
|
| Consciousness | 1 | 1961 | 26 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 58 | 0.010 |
Why?
|
| Volition | 1 | 2001 | 15 | 0.010 |
Why?
|
| Lysergic Acid Diethylamide | 3 | 1973 | 22 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2000 | 24 | 0.010 |
Why?
|
| Rehabilitation | 1 | 2000 | 5 | 0.010 |
Why?
|
| Medical Audit | 1 | 2000 | 41 | 0.010 |
Why?
|
| New York | 1 | 2000 | 69 | 0.010 |
Why?
|
| Cadaver | 1 | 2000 | 185 | 0.010 |
Why?
|
| International Normalized Ratio | 1 | 2000 | 38 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3243 | 0.010 |
Why?
|
| Documentation | 1 | 2000 | 98 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2002 | 222 | 0.010 |
Why?
|
| Cimetidine | 1 | 1979 | 7 | 0.010 |
Why?
|
| Schizophrenia | 3 | 1968 | 464 | 0.010 |
Why?
|
| Pruritus | 1 | 1979 | 26 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 319 | 0.010 |
Why?
|
| Granuloma | 1 | 1998 | 65 | 0.010 |
Why?
|
| Utilization Review | 1 | 1997 | 21 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1998 | 160 | 0.010 |
Why?
|
| Delphi Technique | 1 | 1997 | 80 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2000 | 463 | 0.010 |
Why?
|
| Fluconazole | 1 | 1997 | 10 | 0.010 |
Why?
|
| Deanol | 3 | 1970 | 3 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
| Chlorpromazine | 2 | 1968 | 14 | 0.010 |
Why?
|
| Pentobarbital | 2 | 1967 | 20 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1998 | 238 | 0.010 |
Why?
|
| Base Sequence | 2 | 1992 | 2330 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1992 | 3030 | 0.010 |
Why?
|
| Social Support | 1 | 1997 | 193 | 0.010 |
Why?
|
| Writing | 1 | 1995 | 29 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1995 | 112 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1975 | 347 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2000 | 1065 | 0.010 |
Why?
|
| Auditory Perception | 1 | 1995 | 96 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1995 | 172 | 0.010 |
Why?
|
| Sensation | 1 | 1994 | 45 | 0.010 |
Why?
|
| Peritoneum | 1 | 1994 | 57 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1994 | 82 | 0.010 |
Why?
|
| Psychopharmacology | 1 | 1973 | 26 | 0.010 |
Why?
|
| Nuclear Transfer Techniques | 1 | 1972 | 15 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1994 | 135 | 0.010 |
Why?
|
| Amoeba | 1 | 1972 | 5 | 0.010 |
Why?
|
| Death | 1 | 1993 | 73 | 0.010 |
Why?
|
| Tritium | 1 | 1972 | 133 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1972 | 274 | 0.010 |
Why?
|
| Deoxyribonuclease HpaII | 1 | 1992 | 1 | 0.010 |
Why?
|
| Sex Determination Analysis | 1 | 1992 | 18 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 1973 | 171 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1992 | 30 | 0.010 |
Why?
|
| Oogenesis | 1 | 1992 | 45 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 157 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1995 | 405 | 0.010 |
Why?
|
| Colonoscopy | 1 | 1994 | 264 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1971 | 45 | 0.010 |
Why?
|
| Pain | 1 | 1994 | 391 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1992 | 92 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1973 | 227 | 0.010 |
Why?
|
| Germ Cells | 1 | 1992 | 126 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1992 | 204 | 0.010 |
Why?
|
| Pulse | 1 | 1971 | 18 | 0.010 |
Why?
|
| Genes | 1 | 1992 | 305 | 0.010 |
Why?
|
| Plant Extracts | 1 | 1973 | 244 | 0.010 |
Why?
|
| Methylation | 1 | 1992 | 251 | 0.010 |
Why?
|
| Gestational Age | 1 | 1992 | 311 | 0.010 |
Why?
|
| DMF Index | 1 | 1990 | 1 | 0.010 |
Why?
|
| Oral Hygiene | 1 | 1990 | 3 | 0.010 |
Why?
|
| Dental Plaque Index | 1 | 1990 | 3 | 0.010 |
Why?
|
| Periodontal Index | 1 | 1990 | 4 | 0.010 |
Why?
|
| MMPI | 1 | 1970 | 11 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1970 | 50 | 0.010 |
Why?
|
| Alcoholic Intoxication | 1 | 1990 | 31 | 0.010 |
Why?
|
| Desipramine | 1 | 1970 | 9 | 0.010 |
Why?
|
| Psychological Tests | 1 | 1970 | 91 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1970 | 79 | 0.010 |
Why?
|
| Wakefulness | 1 | 1970 | 134 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 927 | 0.010 |
Why?
|
| Amygdala | 1 | 1970 | 84 | 0.010 |
Why?
|
| Heparinoids | 1 | 1989 | 4 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1988 | 25 | 0.010 |
Why?
|
| DNA Probes | 1 | 1988 | 77 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1989 | 332 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1988 | 129 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1988 | 303 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1988 | 131 | 0.010 |
Why?
|
| Thiopental | 1 | 1967 | 15 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1988 | 782 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 1294 | 0.000 |
Why?
|
| Social Isolation | 1 | 1966 | 67 | 0.000 |
Why?
|
| Orphenadrine | 1 | 1965 | 2 | 0.000 |
Why?
|
| Perphenazine | 1 | 1965 | 2 | 0.000 |
Why?
|
| Barbiturates | 1 | 1965 | 12 | 0.000 |
Why?
|
| Drug Therapy | 1 | 1965 | 70 | 0.000 |
Why?
|
| Caffeine | 1 | 1965 | 81 | 0.000 |
Why?
|
| Hospitals, University | 1 | 1984 | 194 | 0.000 |
Why?
|
| Amino Alcohols | 1 | 1963 | 1 | 0.000 |
Why?
|
| Choline | 1 | 1963 | 23 | 0.000 |
Why?
|
| Stimulation, Chemical | 2 | 1970 | 63 | 0.000 |
Why?
|
| Cholestasis | 1 | 1979 | 47 | 0.000 |
Why?
|
| Injections, Intramuscular | 2 | 1968 | 62 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1970 | 29 | 0.000 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1970 | 6 | 0.000 |
Why?
|